EGFR and lung adenocarcinoma: EGFR is a well‐characterized driver of a subset of lung cancers, with activating alterations predicting sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) reported in 10%–35% of lung adenocarcinomas.4, 5